: The AMEDEO Literature Guide

Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Multiple Sclerosis

Free Subscription

Articles published in J Neurol
Retrieve available abstracts of 348 articles:
HTML format

Single Articles

July 2026

KOKS F, Reubens F, van der Zee H, Briede JJ, et al
The dual role of mTOR in multiple sclerosis pathophysiology: a systematic review.
J Neurol. 2026;273:441.
PubMed Abstract available

ARATAKE Y, Yoshinaga K, Ashida S, Fujii C, et al
Beyond dissemination criteria: lesion-based longitudinal MRI of atypical demyelinating lesions at the boundary of multiple sclerosis.
J Neurol. 2026;273:438.
PubMed Abstract available

June 2026

BOVE R, Langdon D, Maciejowski M, Jasinska E, et al
Efficacy and safety of ofatumumab in participants with relapsing multiple sclerosis and breakthrough disease on oral fingolimod or fumarates: results from the ARTIOS study.
J Neurol. 2026;273:434.
PubMed Abstract available

CALISTRI V, Pezzella FR, Prosperini L
Triple-crush mechanism in multiple sclerosis-associated trigeminal neuralgia.
J Neurol. 2026;273:431.
PubMed

GANGEMI E, Piervincenzi C, Tommasin S, Ojha A, et al
The relationship between cerebellar functional connectivity alterations and hand dexterity impairment in multiple sclerosis.
J Neurol. 2026;273:425.
PubMed Abstract available

MUNOZ-VENDRELL A, Arroyo-Pereiro P, Leon I, Bau L, et al
Serum biomarkers remain stable after transitioning from intravenous to subcutaneous natalizumab in multiple sclerosis.
J Neurol. 2026;273:412.
PubMed Abstract available

WILLEMS S, D'hooghe MB, Sastre-Garriga J, Pareto D, et al
Spinal cord reserve is associated with multi-dimensional clinical resilience in multiple sclerosis.
J Neurol. 2026;273:402.
PubMed Abstract available

GUGER M, Enzinger C, Heschl B, Di Pauli F, et al
The impact of age on efficacy and safety of disease modifying treatment-insights from the Austrian Multiple Sclerosis Treatment Registry.
J Neurol. 2026;273:392.
PubMed Abstract available

FOTTINGER F, Krajnc N, Berek K, Nolte JP, et al
Integration of retinal layer thinning into NEDA-3 predicts disability progression in multiple sclerosis.
J Neurol. 2026;273:382.
PubMed Abstract available

ESPOSITO F, Misra K, Doyle F, Clarelli F, et al
Distinct age-related pattern of mitochondrial somatic mutations across multiple sclerosis phenotypes.
J Neurol. 2026;273:374.
PubMed Abstract available

REUTER E, Luerweg J, Katsimpoura M, Haselon J, et al
Virtual reality-based oculography detects internuclear ophthalmoplegia in multiple sclerosis and other neurological disorders.
J Neurol. 2026;273:372.
PubMed Abstract available

BERGSLAND N, Burnham A, Dwyer MG, Bartnik A, et al
Ultra-low-field MRI for bedside imaging of severe multiple sclerosis.
J Neurol. 2026;273:364.
PubMed Abstract available

TEDONE N, Preziosa P, Pagani E, Meani A, et al
Structural MRI signature of late- versus adult-onset multiple sclerosis: a multiparametric study.
J Neurol. 2026;273:360.
PubMed Abstract available

BET MDA, Helmlinger B, Broeders TAA, Hechenberger SMC, et al
Functional connectivity dynamics of monoaminergic circuits related to fatigue in multiple sclerosis.
J Neurol. 2026;273:354.
PubMed Abstract available

HOF SN, Keytsman E, Fuchs TAN, Wessels MHJ, et al
What if it is the eyes? The effect of eye movement disorders on cognitive testing in MS.
J Neurol. 2026;273:355.
PubMed Abstract available

May 2026

PEGORINI C, Cattaneo D, Meotti M, Baglio F, et al
Artificial intelligence for gait and balance in neurological disorders: a scoping review of clinical applications and technologies.
J Neurol. 2026;273:346.
PubMed Abstract available

SURCINELLI A, Panzera I, Piscaglia MG, Zagnoli S, et al
Late-onset multiple sclerosis is associated with relapse-independent disability accrual: a propensity score-weighted recurrent-event study.
J Neurol. 2026;273:332.
PubMed Abstract available

ROMANO F, Valsasina P, Albergoni M, Amato MP, et al
Increased functional network connectivity following cognitive rehabilitation in progressive multiple sclerosis with moderate to severe disabilty: findings from the CogEx study.
J Neurol. 2026;273:325.
PubMed Abstract available

GUO J, Johansson E, Hillert J, Olsson T, et al
Trajectories of processing speed in multiple sclerosis across disease-modifying therapies.
J Neurol. 2026;273:324.
PubMed Abstract available

BERGAMASCHI R, Ferraro OE, Pisoni E, Fronza M, et al
Correction: Ozone pollution as a possible trigger for multiple sclerosis in young people: the PEDIGREE study.
J Neurol. 2026;273:319.
PubMed

DE JONG DJ, Molenaar PCG, Verhoef V, Novakova L, et al
The practice effect of smartphone-derived cognitive processing speed assessments as a proxy of cognitive functioning in multiple sclerosis.
J Neurol. 2026;273:305.
PubMed Abstract available

MAGGI G, Altieri M, d'Ambrosio A, Risi M, et al
Refining neuropsychological assessment strategies in multiple sclerosis: insights from long-term cognitive trajectories.
J Neurol. 2026;273:304.
PubMed Abstract available

FILIPPI M, D'Amico E, Brescia Morra V, Zanetta C, et al
Ocrelizumab in early relapsing-remitting multiple sclerosis: first interim analysis of the MUSPO Italian prospective cohort.
J Neurol. 2026;273:302.
PubMed Abstract available

April 2026

TUOMAALA J, Saraste M, Smith E, Kuusi M, et al
Association between post-COVID-19 neuropsychiatric symptoms and persistent glial activation in the limbic system: a TSPO PET study.
J Neurol. 2026;273:298.
PubMed Abstract available

PENNER IK, Maier T, Wiemer T, Leemhuis J, et al
Patient profiling in relapsing multiple sclerosis: insights from a real-world observational study into the unmet medical needs of patients on disease-modifying therapy.
J Neurol. 2026;273:292.
PubMed Abstract available

IND G, Hashmi Z, Ahuja S, Fayad T, et al
Demyelinating disorders in women: epidemiology, immunology, and clinical implications across MS, NMOSD, and MOGAD.
J Neurol. 2026;273:290.
PubMed Abstract available

AVEDILLO-SALAS A, Martinez LB, Fanlo-Villacampa A, Vicente-Romero J, et al
Efficacy and safety of monoclonal antibodies in the treatment of relapsing remitting multiple sclerosis: a systematic review.
J Neurol. 2026;273:286.
PubMed Abstract available

BROCHARD V, Lecler A, Januel E, Chaugne E, et al
Optic chiasmal neuritis: clinical features, aetiologies, MRI patterns and prognosis in a real-world cohort.
J Neurol. 2026;273:282.
PubMed Abstract available

FUCHS TAN, Schoonheim MM, Strijbis EMM, Jelgerhuis JR, et al
Predicting disease progression in multiple sclerosis with clinically accessible information and technology.
J Neurol. 2026;273:281.
PubMed Abstract available

SUSINNA C, Restuccia G, Triolo G, Marafioti G, et al
Iron accumulation in multiple sclerosis and implications for cognitive and clinical progression: a systematic review of advanced neuroimaging studies.
J Neurol. 2026;273:275.
PubMed Abstract available

HEGEN H, Fottinger F, Walde J, Berek K, et al
The role of age in choosing high-efficacy treatment for multiple sclerosis: an Austrian MS Database study.
J Neurol. 2026;273:262.
PubMed Abstract available

JARIUS S, Ruprecht K, Metz I, Konig FB, et al
An autoantibody signature predictive for multiple sclerosis: evidence at the protein level and association with histopathological lesion types.
J Neurol. 2026;273:257.
PubMed Abstract available

ZIVADINOV R, Semy M, Bartnik A, Hildesheim FE, et al
Dura mater enhancement on 3T MRI is associated with cortical lesion burden in multiple sclerosis.
J Neurol. 2026;273:251.
PubMed Abstract available

NERI F, Bianchi A, Luchetti L, Breccia D, et al
Functional head impulse testing for detection and quantification of vestibular dysfunction in multiple sclerosis.
J Neurol. 2026;273:245.
PubMed Abstract available

HAYES MTG, Beadnall HN, Merlo D, Monif M, et al
Cross-sectional brain volumetric measures and disability outcomes in relapsing-remitting multiple sclerosis.
J Neurol. 2026;273:243.
PubMed Abstract available

GUO J, Olsson T, Johansson E, Alfredsson L, et al
Long-term disability after initiation of platform versus high-efficacy disease-modifying therapy in relapsing-onset multiple sclerosis.
J Neurol. 2026;273:240.
PubMed Abstract available

March 2026

MONTALBAN X, Hohlfeld R, Pozzilli C, Freedman MS, et al
Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.
J Neurol. 2026;273:234.
PubMed Abstract available

MISCIOSCIA A, Silvestri E, Puthenparampil M, Scialpi G, et al
The cerebellar cognitive affective syndrome scale in early multiple sclerosis.
J Neurol. 2026;273:219.
PubMed Abstract available

WIENDL H, Gold R, Pul R, Ernst M, et al
Treatment-free remission in MS: long-term disease control with cladribine tablets.
J Neurol. 2026;273:218.
PubMed Abstract available

GUERRA T, Lucisano G, Rocca MA, Cocco E, et al
HerMeS: a registry-based evaluation of the HERCULES criteria for identifying nonrelapsing SPMS.
J Neurol. 2026;273:193.
PubMed Abstract available

DIMITRIADOU EM, Tzanetakos D, Theodorou A, Akrivaki A, et al
The predictive value of serum neurofilament light chain in achieving no evidence of disease activity-3 (NEDA-3) status in treatment-naive patients with multiple sclerosis.
J Neurol. 2026;273:194.
PubMed Abstract available

CANDELORO R, Laudisi M, Ferri C, Baldi E, et al
Beyond oligoclonal bands: the independent role of kappa free light chains in the diagnostic workup of multiple sclerosis.
J Neurol. 2026;273:191.
PubMed Abstract available

FREEDMAN DE, Benedict RHB, Oh J, Feinstein A, et al
The non-linear relationship between self-reported cognitive concerns and performance-based cognitive dysfunction in people with multiple sclerosis: a cross-sectional study.
J Neurol. 2026;273:190.
PubMed Abstract available

MOLENAAR PCG, de Jong DJ, Hof SN, van Oirschot P, et al
Digital monitoring of disease activity in relapsing-remitting multiple sclerosis.
J Neurol. 2026;273:186.
PubMed Abstract available

KLEIN KRANENBARG RAM, Blok KM, van Hasselt Y, Melisse S, et al
Symptoms of depression and anxiety are early predictors of multi-domain disability progression in progressive MS.
J Neurol. 2026;273:182.
PubMed Abstract available

BERGAMASCHI R, Ferraro OE, Enrico P, Marzia F, et al
Ozone pollution as a possible trigger for multiple sclerosis in young people: the PEDIGREE study.
J Neurol. 2026;273:172.
PubMed Abstract available

February 2026

SANDROFF BM, Motl RW, Nauman H, Wells GE, et al
Feasibility of a 12-month, remotely delivered and supported aerobic walking exercise training program for brain and cognition in adults with multiple sclerosis.
J Neurol. 2026;273:162.
PubMed Abstract available

GUO J, Olsson T, Alfredsson L, Hedstrom AK, et al
Disability progression in multiple sclerosis: a latent class analysis of predictors.
J Neurol. 2026;273:157.
PubMed Abstract available

QU B, Li S, Chen H, Zhang Y, et al
Disrupted and reorganized connectivity of brain networks in multiple sclerosis: a systematic review and meta-analysis of resting-state functional MRI.
J Neurol. 2026;273:139.
PubMed Abstract available

VAN DEN BOOGAARD LJM, Bochman A, Drenthen GS, Knippenberg SAM, et al
Longitudinal myelin MR imaging in patients with multiple sclerosis: a narrative review.
J Neurol. 2026;273:136.
PubMed Abstract available

CORSTEN CEA, Geraedts VSA, Marques AM, Melief MJ, et al
Serum neurofilament light chain and glial fibrillary acidic protein predicting multiple sclerosis after clinically isolated syndrome.
J Neurol. 2026;273:128.
PubMed Abstract available

FREEDMAN DE, Oh J, Feinstein A
Relationship status and the neurobehavioral symptoms of multiple sclerosis: a cross-sectional analysis.
J Neurol. 2026;273:126.
PubMed Abstract available

GERNERT JA, Zausinger H, Diedrich L, Wicklein R, et al
The potential of optical coherence tomography angiography in progressive multiple sclerosis.
J Neurol. 2026;273:118.
PubMed Abstract available

GUO J, Olsson T, Alfredsson L, Hedstrom AK, et al
Patient-reported gradual worsening reveals progression beyond MS subtypes.
J Neurol. 2026;273:117.
PubMed Abstract available

SOUISSI A, Patti F, Spelman T, Chisari C, et al
Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry.
J Neurol. 2026;273:114.
PubMed Abstract available

January 2026

ZANETTA C, Giordano A, Laserra F, Giliberti A, et al
Environmental risk factors and conversion to multiple sclerosis in subjects with radiologically isolated syndrome: a case-control study.
J Neurol. 2026;273:106.
PubMed Abstract available

ALADRO Y, Alvarez-Saenz de Tejada C, Diaz-Diaz J, Pilo de la Fuente B, et al
Prevalence of restless legs syndrome in patients with multiple sclerosis, as confirmed by sleep disorders specialists.
J Neurol. 2026;273:96.
PubMed Abstract available

BAIAMONTE L, Sera F, Bellante G, Ragonese P, et al
Accuracy of the central vein sign in diagnosis of multiple sclerosis: a systematic review and meta-analysis.
J Neurol. 2026;273:95.
PubMed Abstract available

GYGER N, Monschein T, Filser M, Batge S, et al
Cognitive training, exercise training or combined training? A comparative effectiveness research study on subjective and objective cognitive outcomes in multiple sclerosis.
J Neurol. 2026;273:82.
PubMed Abstract available

GRECO G, Della Porta G, Masi F, Redemagni C, et al
Two-year OCT follow-up in multiple sclerosis patients on Ofatumumab shows retinal preservation over non-antiCD20 treatments.
J Neurol. 2026;273:77.
PubMed Abstract available

December 2025

YANG J, Li H, Zhang Y, Hu S, et al
Correction: Effects of exercise on fatigue and quality of life in multiple sclerosis: a network meta-analysis and systematic review.
J Neurol. 2025;273:51.
PubMed

CHISARI CG, Lo Fermo S, Di Sapio A, Amato MP, et al
Effectiveness of Rituximab in rElapsiNg Multiple SclErosis previously treated with hiGhly-Active Disease modifying thErapies (RENEGADE study).
J Neurol. 2025;273:47.
PubMed Abstract available

RESTUCCIA G, Susinna C, Marafioti G, Rifici C, et al
Serum and cerebrospinal fluid biomarkers as predictors of cognitive impairment in multiple sclerosis: a systematic review of longitudinal studies.
J Neurol. 2025;273:36.
PubMed Abstract available

SURCINELLI A, Massa I, Gentili N, Panzera I, et al
Harmonized magnetic resonance imaging protocols for multiple sclerosis: HARMONY-MS, a pilot project.
J Neurol. 2025;273:39.
PubMed Abstract available

KONITSIOTI AM, Schweitzer F, Johannis W, Steffen F, et al
Serum neurofilament light chain as a biomarker of disease control in multiple sclerosis: a real-world cross-sectional analysis of therapeutic regimens.
J Neurol. 2025;273:34.
PubMed Abstract available

TAN H, Yin Z, Zhangbao J, Li X, et al
Retinal nerve fiber layer thinning in multiple sclerosis: clinical implications, cognitive associations, and effects of disease-modifying therapies.
J Neurol. 2025;273:25.
PubMed Abstract available

BSTEH G, Velez Escola L, Hegen H, Lindner E, et al
Application of optical coherence tomography in multiple sclerosis: consensus recommendations of the Austrian network (AN-OCT-MS).
J Neurol. 2025;273:24.
PubMed Abstract available

TEDONE N, Preziosa P, Meani A, Mistri D, et al
Clinical, functional and cognitive features of late-onset multiple sclerosis.
J Neurol. 2025;273:14.
PubMed Abstract available

ELLINGHAUS CA, Rohling HM, Dorsch EM, Sperber PS, et al
Anchor-based evaluation of digital motor biomarkers from a 2-year observation in 100 patients with multiple sclerosis.
J Neurol. 2025;273:4.
PubMed Abstract available

HEDSTROM AK, Olsson T, Alfredsson L
Determinants and prognostic value of onset symptoms in multiple sclerosis.
J Neurol. 2025;273:2.
PubMed Abstract available

November 2025

WANG Z, Li S, Liu J, Li Y, et al
Nomograms integrating cortical morphometric metrics with 3D multi-parametric MRI radiomics for predicting disability progression and cognitive worsening in relapsing-remitting multiple sclerosis: a multi-center validation study.
J Neurol. 2025;272:792.
PubMed Abstract available

KLEINSCHNITZ C, Skripuletz T, Pfeuffer S, Pawlitzki M, et al
Is therapy-free remission a realistic goal with cladribine tablets in multiple sclerosis? New insights into the mechanism of action and clinical implications of immune reconstitution with cladribine tablets in MS therapy.
J Neurol. 2025;272:788.
PubMed Abstract available

PIERVINCENZI C, Ojha A, Tommasin S, Satriano F, et al
Functional connectivity changes are associated with disability progression in multiple sclerosis: a longitudinal fMRI study.
J Neurol. 2025;272:787.
PubMed Abstract available

BALSHI A, Dempsey JP, Kumbar S, Manning N, et al
Motherhood and diagnostic delay among women with multiple sclerosis.
J Neurol. 2025;272:784.
PubMed Abstract available

YANG X, Li F, Zhe J, Zhang Z, et al
Single-cell RNA sequencing of cerebrospinal fluid immune cells in relapsing-remitting multiple sclerosis: insights into cellular composition and immune dynamics.
J Neurol. 2025;272:778.
PubMed Abstract available

TEDONE N, Grosselle M, Portaccio E, Amato MP, et al
The brief repeatable battery of neuropsychological test (BRB-N) version B: update of Italian normative data.
J Neurol. 2025;272:776.
PubMed Abstract available

MONSCHEIN T, Untersteiner H, Ponleitner M, Krajnc N, et al
Safety of disease-modifying therapies in multiple sclerosis: real-world data from the Austrian MS Treatment Registry (AMSTR).
J Neurol. 2025;272:774.
PubMed Abstract available

MARTIRE MS, Gattuso I, Vezzulli P, Guerrieri S, et al
Unveiling a silent threat: slowly expanding spinal cord lesion linked to clinical worsening in multiple sclerosis: a case report.
J Neurol. 2025;272:773.
PubMed

LADEIRA F, Nobrega C, Cerqueira J
Correction: Evaluation of the efficacy of the SARS-CoV-2 vaccine additional and booster doses in immunocompromised patients with multiple sclerosis: the COVACiMS study.
J Neurol. 2025;272:768.
PubMed

TROJANO M, Iaffaldano P, Copetti M, Drahota J, et al
Big multiple sclerosis data network: novel modelling approaches for real-world data analysis.
J Neurol. 2025;272:754.
PubMed Abstract available

OZAKBAS S, Alizada S, Caliskan C, Simsek Y, et al
Familial multiple sclerosis is associated with accelerated progression to secondary progressive phase: a retrospective single-center cohort study.
J Neurol. 2025;272:749.
PubMed Abstract available

WASKOWIAK PT, de Jong BA, Uitdehaag BMJ, Myronenko A, et al
Cognitive awareness in people with multiple sclerosis before and after neuropsychological assessment.
J Neurol. 2025;272:748.
PubMed Abstract available

MATAS E, Bau L, Romero-Pinel L, Leon I, et al
Benign multiple sclerosis and long-term outcomes after 30 years.
J Neurol. 2025;272:747.
PubMed Abstract available

October 2025

MONTE G, Tiralongo G, Papetti L, Ferilli MAN, et al
Complete Epstein-Barr virus seropositivity in a cohort of pediatric onset multiple sclerosis: a comparison to other autoimmune diseases.
J Neurol. 2025;272:735.
PubMed Abstract available

HUA LH, Brown B, Camacho E, Chinea AR, et al
Switch from intravenous anti-CD20 therapy to subcutaneous ofatumumab in patients with relapsing MS: results from the OLIKOS study.
J Neurol. 2025;272:725.
PubMed Abstract available

ABOSEIF A, Jackson-Tarlton CS, Schwarz CG, Decker PA, et al
Cervical cord atrophy correlates with intracranial lesion burden in tumefactive multiple sclerosis.
J Neurol. 2025;272:717.
PubMed Abstract available

OPFER R, Spies L, Kruger J, Buddenkotte T, et al
Whole brain volume loss is associated with a short-term disability progression in relapse-activity free multiple sclerosis.
J Neurol. 2025;272:715.
PubMed Abstract available

SU X, Zheng Z, Yu F, Liu C, et al
The impact of different exercise types on cognitive function in patients with multiple sclerosis: a systematic review and network meta-analysis.
J Neurol. 2025;272:709.
PubMed Abstract available

PREZIOSA P, Brescia Morra V, Capobianco M, Gasperini C, et al
Efficacy and safety of ublituximab for relapsing multiple sclerosis patients: current evidence and expert opinion.
J Neurol. 2025;272:707.
PubMed Abstract available

LIU R, Kong L, Cao L, Wang H, et al
Retinal microvascular differences between multiple sclerosis and neuromyelitis optica spectrum disorder: a cross-sectional study with diagnostic modeling.
J Neurol. 2025;272:700.
PubMed Abstract available

AHMAD R, Jackson-Tarlton CS, Flanagan EP, Messina S, et al
Critical demyelinating lesions in progressive multiple sclerosis: a prospective observational study.
J Neurol. 2025;272:677.
PubMed Abstract available

September 2025

WAGSHUL ME, Nayak S, Foley FW, Motl RW, et al
Grey matter atrophy patterns of mobility shared across older adults with and without multiple sclerosis.
J Neurol. 2025;272:656.
PubMed Abstract available

ROMANO F, Rocca MA, Pagani E, Amato MP, et al
Effects of cognitive rehabilitation and exercise on brain structure in progressive multiple sclerosis: results from the CogEx trial.
J Neurol. 2025;272:645.
PubMed Abstract available

MORENO-NAVARRO L, Mora-Diaz S, Ruiz-Escribano-Menchen L, Sempere AP, et al
Kappa free light chain index as a diagnostic and prognostic biomarker in multiple sclerosis.
J Neurol. 2025;272:646.
PubMed Abstract available

HABEK M, Adamec I, Gabelic T, Barun B, et al
Diagnostic performance of the 2010, 2017, and 2024 McDonald criteria: clinical implications in multiple sclerosis.
J Neurol. 2025;272:637.
PubMed Abstract available

ALONI R, Dror C, Barazani T, Kalron A, et al
Wartime stress and relapse risk in people with multiple sclerosis: a prospective cohort study.
J Neurol. 2025;272:619.
PubMed Abstract available

YANG J, Li H, Zhang Y, Hu S, et al
Effects of exercise on fatigue and quality of life in multiple sclerosis: a network meta-analysis and systematic review.
J Neurol. 2025;272:621.
PubMed Abstract available

ELLENBERGER D, Frahm N, Stahmann A, Warnke C, et al
Age-related differences in switching highly effective disease-modifying therapy in patients with multiple sclerosis.
J Neurol. 2025;272:609.
PubMed Abstract available

ASLAN D, Bourabia S, Kowall B, Straukiene A, et al
The impact of autoimmune comorbidities on multiple sclerosis progression: insights from a longitudinal single-center study.
J Neurol. 2025;272:607.
PubMed Abstract available

August 2025

KEVER A, Kang N, Meza C, Pogacar M, et al
Not for everyone: examining predictors of cognitive rehabilitation success in multiple sclerosis.
J Neurol. 2025;272:593.
PubMed

MATHEY G, Epstein J, Alix T, Julien M, et al
Cerebrospinal fluid levels of chitinase 3-like 1 and interleukin-6 can predict response to platform therapies in relapsing multiple sclerosis.
J Neurol. 2025;272:592.
PubMed Abstract available

ADAMMEK F, Gralla W, Kupjetz M, Rademacher A, et al
Functional exercise training in persons with multiple sclerosis: a systematic review.
J Neurol. 2025;272:590.
PubMed Abstract available

REEVES JA, Tranquille A, Bartnik A, Mohebbi M, et al
Paramagnetic rim lesions are associated with choroid plexus inflammation and expansion over 5 years in people with multiple sclerosis.
J Neurol. 2025;272:585.
PubMed Abstract available

SCANDIFFIO J, Langer LK, Senthilnathan V, Feng G, et al
Effects of psychological therapies in people with multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials.
J Neurol. 2025;272:584.
PubMed Abstract available

GUERRIERI S, Gattuso I, Genchi A, Nozzolillo A, et al
Stratify and ImmunoWELL JCV tests performances in a real-world multiple sclerosis cohort: possible clinical implications of biosimilar Natalizumab use.
J Neurol. 2025;272:583.
PubMed

ABBADESSA G, Maida E, Bonavita S, Lavorgna L, et al
First the B cells fall, then the T cells follow: temporal immunological shift with ocrelizumab in multiple sclerosis.
J Neurol. 2025;272:582.
PubMed Abstract available

JAWORSKI M 3RD, Balconi J, Santivasci C, Youngs M, et al
Improving conscientiousness through a smartphone app and telecoaching intervention: insights from multiple sclerosis and healthy aging samples.
J Neurol. 2025;272:580.
PubMed Abstract available

SBAIHAT H, Roenneke K, Muller D, Ladopoulos T, et al
MRI-based human brain atlases of R1, R2, proton density, and myelin volume fraction using synthetic quantitative imaging at 1.5 T.
J Neurol. 2025;272:578.
PubMed Abstract available

ALFREDSSON L, Guo J, Johansson E, Olsson T, et al
Early-life and adult body mass index in relation to MS disability progression.
J Neurol. 2025;272:571.
PubMed Abstract available

FILIPPI M, Amato MP, Centonze D, Gallo P, et al
The use of high-efficacy disease-modifying therapies in multiple sclerosis: recommendations from an expert Delphi consensus.
J Neurol. 2025;272:565.
PubMed Abstract available

LEITNER U, Chew SH, Blanch J, Viswanathan M, et al
Characteristics of MRI lesions in AQP4 antibody-positive NMOSD, MOGAD, and multiple sclerosis: a systematic review and meta-analysis.
J Neurol. 2025;272:560.
PubMed Abstract available

MANISCALCO GT, Sparaco M, Di Gregorio M, Cafasso G, et al
Real-world comparison of lymphopenia profiles in S1P receptor modulators for multiple sclerosis: a multicenter retrospective study.
J Neurol. 2025;272:559.
PubMed Abstract available

KERITAM O, Ascoli O, Harsanyi A, Cetin H, et al
Advanced multiple sclerosis: an exploratory study on a neglected patient population.
J Neurol. 2025;272:553.
PubMed Abstract available

MENASCU S, Drori T, Kalron A
Subcortical brain volume changes linked to concern of falling in multiple sclerosis: a structural MRI study.
J Neurol. 2025;272:552.
PubMed Abstract available

July 2025

DE SOUZA WAGNER PH, de Paiva FA, Mello JS, Silva ALM, et al
Clinical outcomes after switching from fingolimod to B-cell-depleting therapies in multiple sclerosis: systematic review and meta-analysis.
J Neurol. 2025;272:546.
PubMed Abstract available

DINI M, Tacchini M, Gamberini G, Boschetti A, et al
Learning as a digital hallmark of cognition in multiple sclerosis: lessons from a digital symbol digit modalities test.
J Neurol. 2025;272:536.
PubMed Abstract available

FUNG WH, Wessels MHJ, Coerver EME, de Beukelaar J, et al
Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS).
J Neurol. 2025;272:530.
PubMed Abstract available

VITTURI BK, Cellerino M, Boccia D, Leray E, et al
Environmental risk factors for multiple sclerosis: a comprehensive systematic review and meta-analysis.
J Neurol. 2025;272:513.
PubMed Abstract available

COLEMAN A, Touze A, Farag M, Pengo M, et al
Evaluating finger-prick blood collection for remote quantification of neurofilament light in neurological diseases.
J Neurol. 2025;272:501.
PubMed Abstract available

NICOLELLA V, Varelli M, Fasano S, Sirica R, et al
Clinical application of age-derived cut-offs for plasma neurofilament light chain in multiple sclerosis.
J Neurol. 2025;272:495.
PubMed Abstract available

CAGOL A, Schaedelin S, Ocampo-Pineda M, Benkert P, et al
Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis Cohort.
J Neurol. 2025;272:491.
PubMed Abstract available

June 2025

ZACCONE T, Moiola L, Guerrieri S, Nozzolillo A, et al
Long-term effectiveness and safety of ocrelizumab: a single-centre real-world study.
J Neurol. 2025;272:481.
PubMed Abstract available

VERCELLINO M, Marasciulo S, Bosa C, Rolando A, et al
Added value of spinal cord MRI in detecting active disease in non-relapsing progressive multiple sclerosis patients.
J Neurol. 2025;272:482.
PubMed Abstract available

NAUTA IM, Loughlin KNM, Gravesteijn AS, van Wegen J, et al
A multi-domain lifestyle intervention in multiple sclerosis: a longitudinal observational study.
J Neurol. 2025;272:476.
PubMed Abstract available

BURGUET VILLENA F, Cerda-Fuertes N, Hofer L, Schadelin S, et al
Retinal neuronal loss and progression independent of relapse activity in multiple sclerosis.
J Neurol. 2025;272:454.
PubMed Abstract available

ZANETTA C, Gasperini C, Amato MP, Centonze D, et al
Potential use of the SARS-CoV-2 monoclonal antibody sipavibart in people with multiple sclerosis: definition of different patient archetypes from an Italian expert group perspective.
J Neurol. 2025;272:446.
PubMed Abstract available

CHEN H
A disproportionality analysis of nervous system adverse events associated with disease-modifying therapies in multiple sclerosis: insights from the FDA adverse event reporting system (FAERS).
J Neurol. 2025;272:445.
PubMed Abstract available

MALUCCHI S, Bava CI, Valentino P, Martire S, et al
Correction: In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting.
J Neurol. 2025;272:444.
PubMed

May 2025

NEYAL N, Krey KJ, Morrison HA, Nathoo N, et al
From checkboxes to emojis: a novel approach to patient-reported outcomes in multiple sclerosis.
J Neurol. 2025;272:434.
PubMed Abstract available

CLARELLI F, Corona A, Paakkonen K, Sorosina M, et al
Correction: Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study.
J Neurol. 2025;272:423.
PubMed

GASPERINI C, Centonze D, Conte A, Gallo P, et al
Personalized therapy in multiple sclerosis: an Italian Delphi consensus.
J Neurol. 2025;272:428.
PubMed Abstract available

GIOFRE F, Lugaresi A, Baccari F, Lui E, et al
The topography of infratentorial lesions in depression and anxiety in multiple sclerosis.
J Neurol. 2025;272:420.
PubMed Abstract available

DAVIES L, Shehadeh R, Watkins WJ, Jolles S, et al
Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis.
J Neurol. 2025;272:415.
PubMed Abstract available

ZHANG Y, Li G, Su H, Liang Y, et al
Effects of exercise on balance function in people with multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials.
J Neurol. 2025;272:405.
PubMed Abstract available

GERVASONI E, Torchio A, Bertoni R, Chieffo R, et al
Beyond EDSS: multidomain impairments are detectable and associated with walking disorders in low-disabled people with multiple sclerosis.
J Neurol. 2025;272:404.
PubMed Abstract available

FREEDMAN MS, Abdelhak A, Bhutani MK, Freeman J, et al
The role of serum neurofilament light (sNfL) as a biomarker in multiple sclerosis: insights from a systematic review.
J Neurol. 2025;272:400.
PubMed Abstract available

TARANU D, Balz LT, Holbrook J, Tumani V, et al
Cognitive impairment, mood, and fatigue in various multiple sclerosis subtypes: a one-year follow-up study.
J Neurol. 2025;272:398.
PubMed Abstract available

ROCCA MA, Ratzinger S, Preziosa P, Meani A, et al
Clinical integration of brain and cord MRI features improves differential diagnosis of multiple sclerosis.
J Neurol. 2025;272:388.
PubMed Abstract available

FILIPPI M, Preziosa P, Rocca MA
Randomized controlled trials for multiple sclerosis: integrating pathology-driven outcomes to capture therapeutic efficacy.
J Neurol. 2025;272:385.
PubMed

FREEDMAN DE, Oh J, Einstein G, Feinstein A, et al
Aging and the neuropsychiatry of multiple sclerosis: a cross-sectional study.
J Neurol. 2025;272:375.
PubMed Abstract available

KOLB H, Shachaf Y, Fainberg K, Golan M, et al
Intrathecal methotrexate in progressive multiple sclerosis: a phase 1 open-label study with long-term follow-up.
J Neurol. 2025;272:374.
PubMed Abstract available

HERMAN D, Tanniou J, Leray E, Pierret C, et al
Analyzing recurrent events in multiple sclerosis: a review of statistical models with application to the MSOAC database.
J Neurol. 2025;272:371.
PubMed Abstract available

KUUTTI K, Laakso SM, Viitala M, Atula S, et al
Mortality and causes of death for people with multiple sclerosis: a Finnish nationwide register study.
J Neurol. 2025;272:370.
PubMed Abstract available

April 2025

CACCIAGUERRA L, Madhavan A, Sechi E, Krecke KN, et al
Utility of spinal cord axial-T2 sequence in a population-based cohort of multiple sclerosis.
J Neurol. 2025;272:367.
PubMed

MAHMOUDI N, Renne J, Konen FF, Jendretzky KF, et al
Added value of optic nerve lesions for multiple sclerosis diagnostic criteria.
J Neurol. 2025;272:358.
PubMed Abstract available

LEAVITT V, Mostert J, Comtois J, Moral E, et al
Measuring cognitive change in secondary progressive MS: an analysis of the ASCEND cognition substudy.
J Neurol. 2025;272:338.
PubMed Abstract available

BALSHI A, Dempsey J, Kumbar S, Leuenberger G, et al
Correction: Marriage is associated with decreased lesion volumes and less brain atrophy in people with multiple sclerosis.
J Neurol. 2025;272:337.
PubMed

OJHA A, Tommasin S, Piervincenzi C, Baione V, et al
Clinical and MRI features contributing to the clinico-radiological dissociation in a large cohort of people with multiple sclerosis.
J Neurol. 2025;272:327.
PubMed Abstract available

HONG J, Gaubert M, Lefort M, Ferre JC, et al
Limited added value of systematic spinal cord MRI vs brain MRI alone to classify patients with MS as active or inactive during follow-up.
J Neurol. 2025;272:316.
PubMed Abstract available

MOIOLA L, Mandelli A, Tarkowski M, Finardi A, et al
Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab.
J Neurol. 2025;272:314.
PubMed Abstract available

LADOPOULOS T, Abbas Z, Krieger B, Bellenberg B, et al
Neurological disability and brain grey matter atrophy in primary progressive multiple sclerosis are determined by microstructural lesional changes, but not by lesion load.
J Neurol. 2025;272:302.
PubMed Abstract available

March 2025

KONITSIOTI AM, Laurent S, Ellenberger D, Stahmann A, et al
MS treatment trends before, during, and after the COVID-19 pandemic: insights from the German MS Register.
J Neurol. 2025;272:294.
PubMed Abstract available

LADEIRA F, Nobrega C, Cerqueira J
Evaluation of the efficacy of the SARS-CoV-2 vaccine additional and booster doses in immunocompromised patients with multiple sclerosis: the COVACiMS study.
J Neurol. 2025;272:288.
PubMed Abstract available

BOSTAN M, Li C, Cheong JW, Wong DWK, et al
Longitudinal analysis of retinal and choriocapillaris in patients with multiple sclerosis: a 3-year study.
J Neurol. 2025;272:237.
PubMed Abstract available

February 2025

AZZIMONTI M, Preziosa P, Pagani E, Meani A, et al
Cervical spinal cord gray matter damage predicts disability worsening in multiple sclerosis: a longitudinal study.
J Neurol. 2025;272:228.
PubMed Abstract available

SCHONHERR C, Ziegler J, Zentek T, Rashid A, et al
Smartphone-based gait analysis in the assessment of fatigue and fatigability in people with multiple sclerosis: a supervised cohort study.
J Neurol. 2025;272:217.
PubMed Abstract available

BALSHI A, Dempsey J, Manning N, Leuenberger G, et al
A disproportionality analysis of surgical site infections across multiple sclerosis disease modifying therapies.
J Neurol. 2025;272:223.
PubMed Abstract available

NAYAK S, Wagshul ME, Foley FW, Motl RW, et al
Associations between connectivity in functional brain networks and gait speed in older adults with and without multiple sclerosis.
J Neurol. 2025;272:216.
PubMed Abstract available

DI SABATINO E, Ferraro D, Gaetani L, Emiliano E, et al
CSF biomarkers of B-cell activation in multiple sclerosis: a clinical perspective.
J Neurol. 2025;272:211.
PubMed Abstract available

MARASTONI D, Sicchieri M, Pizzini FB, Scartezzini A, et al
Multiple sclerosis diagnosis and its differential diagnosis in patients presenting with type four 'mirror pattern' CSF oligoclonal bands.
J Neurol. 2025;272:207.
PubMed Abstract available

FILIPPI M, Amato MP, Avolio C, Gallo P, et al
Towards a biological view of multiple sclerosis from early subtle to clinical progression: an expert opinion.
J Neurol. 2025;272:179.
PubMed Abstract available

January 2025

GIANNOPAPAS V, Smyrni V, Kitsos DK, Stefanou MI, et al
Cancer in multiple sclerosis patients following prolonged exposure to disease-modifying therapies (DMTs): a systematic review and meta-analysis.
J Neurol. 2025;272:162.
PubMed Abstract available

INOJOSA H, Schriefer D, Ness NH, Dillenseger A, et al
Cost-consequence analysis of early vs. delayed natalizumab use in highly active relapsing-remitting multiple sclerosis: a simulation study.
J Neurol. 2025;272:153.
PubMed Abstract available

PIHL-JENSEN G, Frederiksen JL
The value of magnetic resonance imaging of the optic nerve for the diagnosis of multiple sclerosis in patients with optic neuritis.
J Neurol. 2025;272:131.
PubMed Abstract available

LAGEMAN SB, Jolly A, Sahi N, Prados F, et al
Explaining cognitive function in multiple sclerosis through networks of grey and white matter features: a joint independent component analysis.
J Neurol. 2025;272:142.
PubMed Abstract available

MIRMOSAYYEB O, Weinstock-Guttman B, Zivadinov R, Jakimovski D, et al
Anatomy-driven segmentation of parafoveal optical coherence tomography (OCT) measures may improve associations with clinical outcomes in multiple sclerosis.
J Neurol. 2025;272:141.
PubMed Abstract available

BALSHI A, Dempsey J, Kumbar S, Leunberger G, et al
Marriage is associated with decreased lesion volumes and less brain atrophy in people with multiple sclerosis.
J Neurol. 2025;272:151.
PubMed Abstract available

MAR S, Valeriani M, Steinborn B, Schreiner T, et al
Ocrelizumab dose selection for treatment of pediatric relapsing-remitting multiple sclerosis: results of the OPERETTA I study.
J Neurol. 2025;272:137.
PubMed Abstract available

MAIWORM M, Koerbel K, Anschutz V, Jakob J, et al
BDNF levels in serum and CSF are associated with clinicoradiological characteristics of aggressive disease in MS patients.
J Neurol. 2025;272:147.
PubMed Abstract available

PREZIOSA P, Pagani E, Meani A, Margoni M, et al
Soma and neurite density abnormalities of paramagnetic rim lesions and core-sign lesions in multiple sclerosis.
J Neurol. 2025;272:145.
PubMed Abstract available

PLESS S, Woelfle T, Lorscheider J, Wiencierz A, et al
CoGames: Development of an adaptive smartphone-based and gamified monitoring tool for cognitive function in Multiple Sclerosis.
J Neurol. 2025;272:119.
PubMed Abstract available

ZANGHI A, Greco A, Giancipoli E, Tumani H, et al
Unraveling the inflammation-degeneration tangle in early MS: preliminary insights from ferritin, neurogranin, TREM2, and retinal ganglion cell layer.
J Neurol. 2025;272:109.
PubMed Abstract available

ROBERTSON NP
Bruton's tyrosine kinase inhibitor for multiple sclerosis: new hope or false dawn.
J Neurol. 2025;272:106.
PubMed Abstract available

WALBAUM M, Madhukar A, Dobson R, Cyhlarova E, et al
Cost effectiveness of different treatment strategies with natalizumab for pregnant women with multiple sclerosis.
J Neurol. 2025;272:93.
PubMed Abstract available

FILIPPI M, Gallo P, Gasperini C, Marfia GA, et al
Implementing proximity care for people with multiple sclerosis in Italy: the bottom-up approach of the StayHome project.
J Neurol. 2025;272:96.
PubMed Abstract available

December 2024

NICOLESCU M, Haussler V, Paul F, Oertel FC, et al
Visual quality of life in NMOSD and MOGAD: profiles, dynamics and associations with ageing and vision.
J Neurol. 2024;272:86.
PubMed Abstract available

BARBA L, Gaetani L, Sperandei S, Di Sabatino E, et al
CSF synaptic biomarkers and cognitive impairment in multiple sclerosis.
J Neurol. 2024;272:85.
PubMed Abstract available

MIRMOSAYYEB O, Yazdan Panah M, Moases Ghaffary E, Vaheb S, et al
Magnetic resonance imaging-based biomarkers of multiple sclerosis and neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.
J Neurol. 2024;272:77.
PubMed Abstract available

FILIPPI M, Margoni M, Zaccone T, Guerrieri S, et al
Disability worsening outcome in multiple sclerosis based on EDSS: does half a point matter?
J Neurol. 2024;272:9.
PubMed

VECCHIO D, Puricelli C, Virgilio E, Passarelli F, et al
Kappa index for multiple sclerosis diagnosis: an accurate biomarker of intrathecal synthesis.
J Neurol. 2024;272:30.
PubMed Abstract available

PONZIO M, Santoni L, Molina M, Tavazzi E, et al
Economic burden of multiple sclerosis in an Italian cohort of patients on disease-modifying therapy: analysis of disease cost and its components.
J Neurol. 2024;272:50.
PubMed Abstract available

DE BLASIIS P, Massimiani A, Inglese C, Bianchini E, et al
Spasticity patterns assessment and recognition for therapeutic approaches (SPARTA) in multiple sclerosis: a multicenter epidemiological study.
J Neurol. 2024;272:34.
PubMed Abstract available

GASPERINI C, Battaglia MA, Balzani F, Chiarini E, et al
Unveiling preferences in multiple sclerosis care: insights from an Italian discrete-choice experiment with patients and healthcare professionals.
J Neurol. 2024;272:27.
PubMed Abstract available

COMABELLA M, Hegen H, Villar LM, Rejdak K, et al
Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis.
J Neurol. 2024;272:26.
PubMed Abstract available

November 2024

PAKEERATHAN T, Havla J, Schwake C, Salmen A, et al
Rapid differentiation of MOGAD and MS after a single optic neuritis.
J Neurol. 2024;271:7222-7231.
PubMed Abstract available

October 2024

FACCIORUSSO S, Malfitano C, Giordano M, Del Furia MJ, et al
Effectiveness of robotic rehabilitation for gait and balance in people with multiple sclerosis: a systematic review.
J Neurol. 2024 Oct 10. doi: 10.1007/s00415-024-12715.
PubMed Abstract available

SELMAJ K, Hartung HP, Mycko MP, Selmaj I, et al
MS treatment de-escalation: review and commentary.
J Neurol. 2024;271:6426-6438.
PubMed Abstract available

September 2024

MALUCCHI S, Bava CI, Valentino P, Martire S, et al
In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting.
J Neurol. 2024 Sep 23. doi: 10.1007/s00415-024-12701.
PubMed Abstract available

MARGONI M, Valsasina P, Moiola L, Mistri D, et al
Monoaminergic network abnormalities are associated with fatigue in pediatric multiple sclerosis.
J Neurol. 2024 Sep 19. doi: 10.1007/s00415-024-12689.
PubMed Abstract available

YOUSEF H, Malagurski Tortei B, Castiglione F
Predicting multiple sclerosis disease progression and outcomes with machine learning and MRI-based biomarkers: a review.
J Neurol. 2024 Sep 12. doi: 10.1007/s00415-024-12651.
PubMed Abstract available

CLARELLI F, Corona A, Paakkonen K, Sorosina M, et al
Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study.
J Neurol. 2024 Sep 12. doi: 10.1007/s00415-024-12608.
PubMed Abstract available

CALLEN AM, Zurawski J, Chu R, Tie Y, et al
The role of 7 T MRI to assess atrophy of the subcortical deep gray matter in relapsing-remitting multiple sclerosis.
J Neurol. 2024 Sep 6. doi: 10.1007/s00415-024-12656.
PubMed Abstract available

DELUCA J
Correction to: Fatigue in multiple sclerosis: can we measure it and can we treat it?
J Neurol. 2024 Sep 6. doi: 10.1007/s00415-024-12630.
PubMed

PORTACCIO E, Betti M, De Meo E, Addazio I, et al
Correction to: Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression.
J Neurol. 2024 Sep 4. doi: 10.1007/s00415-024-12627.
PubMed

GIOSSI R, Mercenari M, Filippi M, Zanetta C, et al
Correction to: Unprescribed cannabinoids and multiple sclerosis: a multicenter, cross-sectional, epidemiological study in Lombardy, Italy.
J Neurol. 2024 Sep 3. doi: 10.1007/s00415-024-12560.
PubMed

August 2024

WURDACK K, Pruss H, Finke C
Evolution from viral encephalitis to autoimmune encephalitis to multiple sclerosis: a case report.
J Neurol. 2024 Aug 31. doi: 10.1007/s00415-024-12659.
PubMed Abstract available

CHISARI CG, Amato MP, Di Sapio A, Foschi M, et al
Active and non-active secondary progressive multiple sclerosis patients exhibit similar disability progression: results of an Italian MS registry study (ASPERA).
J Neurol. 2024 Aug 27. doi: 10.1007/s00415-024-12621.
PubMed Abstract available

CAROTENUTO A, Di Monaco C, Papetti L, Borriello G, et al
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod.
J Neurol. 2024 Aug 23. doi: 10.1007/s00415-024-12610.
PubMed Abstract available

SIMONE M, Lucisano G, Guerra T, Paolicelli D, et al
Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis.
J Neurol. 2024 Aug 23. doi: 10.1007/s00415-024-12638.
PubMed Abstract available

MISCIOSCIA A, Mainero C, Treaba CA, Silvestri E, et al
The contribution of paramagnetic rim and cortical lesions to physical and cognitive disability at multiple sclerosis clinical onset: evaluating the power of MRI and OCT biomarkers.
J Neurol. 2024 Aug 19. doi: 10.1007/s00415-024-12622.
PubMed Abstract available

ARNETT SV, Prain K, Ramanathan S, Bhuta S, et al
Long-term outcomes of ADEM-like and tumefactive presentations of CNS demyelination: a case-comparison analysis.
J Neurol. 2024;271:5275-5289.
PubMed Abstract available

ZIVADINOV R, Jakimovski D, Burnham A, Kuhle J, et al
Neuroimaging assessment of facility-bound severely-affected MS reveals the critical role of cortical gray matter pathology: results from the CASA-MS case-controlled study.
J Neurol. 2024;271:4949-4962.
PubMed Abstract available

July 2024

FILIPPI M, Pagani E, Turrini R, Bartezaghi M, et al
Effects of fingolimod on focal and diffuse damage in patients with relapsing-remitting multiple sclerosis - The "EVOLUTION" study.
J Neurol. 2024 Jul 29. doi: 10.1007/s00415-024-12590.
PubMed Abstract available

MANZANO GS, Levy M, Salky R, Mateen FJ, et al
Assessment of international MOGAD diagnostic criteria in patients with overlapping MOG-associated disease and multiple sclerosis phenotypes.
J Neurol. 2024 Jul 27. doi: 10.1007/s00415-024-12585.
PubMed Abstract available

PASSALI M, Galea I, Knudsen MH, Lau LC, et al
Cerebrospinal fluid neurofilament light chain in acute optic neuritis and its predictive ability of multiple sclerosis.
J Neurol. 2024 Jul 25. doi: 10.1007/s00415-024-12587.
PubMed Abstract available

KARL AS, Klimas R, Katsimpoura M, Sgodzai M, et al
Quality of life and tolerability of B-cell directed therapy of multiple sclerosis with ofatumumab in a patient-centered real-world observational study.
J Neurol. 2024 Jul 22. doi: 10.1007/s00415-024-12581.
PubMed Abstract available

MOLENAAR PCG, Noteboom S, van Nederpelt DR, Krijnen EA, et al
Digital outcome measures are associated with brain atrophy in patients with multiple sclerosis.
J Neurol. 2024 Jul 15. doi: 10.1007/s00415-024-12516.
PubMed Abstract available

RAVANO V, Andelova M, Piredda GF, Sommer S, et al
Microstructural characterization of multiple sclerosis lesion phenotypes using multiparametric longitudinal analysis.
J Neurol. 2024 Jul 13. doi: 10.1007/s00415-024-12568.
PubMed Abstract available

VITI V, Zanetta C, Capra R, Municchi A, et al
Ocrelizumab-associated enteritis in patients with multiple sclerosis: an emerging safety issue.
J Neurol. 2024 Jul 11. doi: 10.1007/s00415-024-12553.
PubMed

DELUCA J
Fatigue in multiple sclerosis: can we measure it and can we treat it?
J Neurol. 2024 Jul 5. doi: 10.1007/s00415-024-12524.
PubMed Abstract available

ROT U, Jerala M, Horvat Ledinek A, Brecl Jakob G, et al
Progressive multifocal leukoencephalopathy in association with siponimod treatment for secondary progressive multiple sclerosis: a case report.
J Neurol. 2024 Jul 3. doi: 10.1007/s00415-024-12542.
PubMed

KAPPOS L, Edan G, Freedman MS, Hartung HP, et al
Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial.
J Neurol. 2024;271:4599-4609.
PubMed Abstract available

ZANGHI A, Borriello G, Bonavita S, Fantozzi R, et al
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study.
J Neurol. 2024;271:4495-4502.
PubMed Abstract available

HARTUNG HP, Berger T, Bermel RA, Brochet B, et al
ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial.
J Neurol. 2024;271:4348-4360.
PubMed Abstract available

MAKHANI N, Lebrun-Frenay C, Siva A, Shabanova V, et al
The diagnostic workup of children with the radiologically isolated syndrome differs by age and by sex.
J Neurol. 2024;271:4019-4027.
PubMed Abstract available

June 2024

LAL AP, Foong YC, Sanfilippo PG, Spelman T, et al
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic.
J Neurol. 2024 Jun 27. doi: 10.1007/s00415-024-12518.
PubMed Abstract available

NOTEBOOM S, Seiler M, Chien C, Rane RP, et al
Evaluation of machine learning-based classification of clinical impairment and prediction of clinical worsening in multiple sclerosis.
J Neurol. 2024 Jun 23. doi: 10.1007/s00415-024-12507.
PubMed Abstract available

SIMANI L, Molaeipour L, Kian S, Leavitt VM, et al
Correlation between cognitive changes and neuroradiological changes over time in multiple sclerosis: a systematic review and meta-analysis.
J Neurol. 2024 Jun 18. doi: 10.1007/s00415-024-12517.
PubMed Abstract available

GIOSSI R, Mercenari M, Filippi M, Zanetta C, et al
Unprescribed cannabinoids and multiple sclerosis: a multicenter, cross-sectional, epidemiological study in Lombardy, Italy.
J Neurol. 2024 Jun 7. doi: 10.1007/s00415-024-12472.
PubMed Abstract available

May 2024

PORTACCIO E, Betti M, De Meo E, Addazio I, et al
Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression.
J Neurol. 2024 May 28. doi: 10.1007/s00415-024-12448.
PubMed Abstract available

MONTEIRO I, Nicolella V, Fiorenza M, Novarella F, et al
The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis.
J Neurol. 2024 May 23. doi: 10.1007/s00415-024-12434.
PubMed Abstract available

CORTESE R, Battaglini M, Stromillo ML, Luchetti L, et al
Regional hippocampal atrophy reflects memory impairment in patients with early relapsing remitting multiple sclerosis.
J Neurol. 2024 May 14. doi: 10.1007/s00415-024-12290.
PubMed Abstract available

WOLF E, Wicklein R, Aly L, Schmaderer C, et al
Optical coherence tomography angiography suggests different retinal pathologies in multiple sclerosis and Sjogren's syndrome.
J Neurol. 2024 May 14. doi: 10.1007/s00415-024-12414.
PubMed Abstract available

FREEDMAN DE, Oh J, Kiss A, Puopolo J, et al
The influence of depression and anxiety on cognition in people with multiple sclerosis: a cross-sectional analysis.
J Neurol. 2024 May 11. doi: 10.1007/s00415-024-12409.
PubMed Abstract available

BARDEL B, Creange A, Bonardet N, Bapst B, et al
Motor function in multiple sclerosis assessed by navigated transcranial magnetic stimulation mapping.
J Neurol. 2024 May 6. doi: 10.1007/s00415-024-12398.
PubMed Abstract available

GALPERIN I, Buzaglo D, Gazit E, Shimoni N, et al
Gait and heart rate: do they measure trait or state physical fatigue in people with multiple sclerosis?
J Neurol. 2024 May 2. doi: 10.1007/s00415-024-12339.
PubMed Abstract available

ROCCA MA, Romano F, Tedone N, Filippi M, et al
Advanced neuroimaging techniques to explore the effects of motor and cognitive rehabilitation in multiple sclerosis.
J Neurol. 2024 May 1. doi: 10.1007/s00415-024-12395.
PubMed Abstract available

PREZIOSA P, Rocca MA, Filippi M
Radiologically isolated syndromes: to treat or not to treat?
J Neurol. 2024;271:2370-2378.
PubMed Abstract available

April 2024

DIMAURO KA, Swetlik C, Cohen JA
Management of multiple sclerosis in older adults: review of current evidence and future perspectives.
J Neurol. 2024 Apr 30. doi: 10.1007/s00415-024-12384.
PubMed Abstract available

ROSENSTEIN I, Nordin A, Sabir H, Malmestrom C, et al
Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple sclerosis.
J Neurol. 2024 Apr 26. doi: 10.1007/s00415-024-12389.
PubMed Abstract available

NAUTA IM, van Dam M, Bertens D, Kessels RPC, et al
Improved quality of life and psychological symptoms following mindfulness and cognitive rehabilitation in multiple sclerosis and their mediating role for cognition: a randomized controlled trial.
J Neurol. 2024 Apr 23. doi: 10.1007/s00415-024-12327.
PubMed Abstract available

SPIEZIA AL, Scalia G, Petracca M, Caliendo D, et al
Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications.
J Neurol. 2024 Apr 17. doi: 10.1007/s00415-024-12362.
PubMed Abstract available

HIRT J, Dembowska K, Woelfle T, Axfors C, et al
Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis.
J Neurol. 2024 Apr 16. doi: 10.1007/s00415-024-12366.
PubMed Abstract available

SINGER BA, Feng J, Chiong-Rivero H
Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption.
J Neurol. 2024 Apr 14. doi: 10.1007/s00415-024-12305.
PubMed Abstract available

STALTER J, Pars K, Witt K
Accelerated long-term forgetting reveals everyday memory deficits in early-stage multiple sclerosis.
J Neurol. 2024 Apr 8. doi: 10.1007/s00415-024-12359.
PubMed Abstract available

CELIK M, Baba C, Irmak C, Ozakbas S, et al
Risk of hepatitis B virus reactivation in people with multiple sclerosis treated with ocrelizumab: an observational study from Turkey.
J Neurol. 2024 Apr 5. doi: 10.1007/s00415-024-12333.
PubMed Abstract available

STEFANOU MI, Giannopapas V, Kitsos DK, Chondrogianni M, et al
Prevalence and epidemiology of stroke in patients with multiple sclerosis: a systematic review and meta-analysis.
J Neurol. 2024 Apr 4. doi: 10.1007/s00415-024-12331.
PubMed Abstract available

MAIDA E, Moccia M, Palladino R, Borriello G, et al
ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis.
J Neurol. 2024 Apr 3. doi: 10.1007/s00415-024-12328.
PubMed Abstract available

SIGNORIELLO E, Foschi M, Lanzillo R, Frau J, et al
Pregnancy effect on disease activity in women with multiple sclerosis treated with cladribine.
J Neurol. 2024 Apr 3. doi: 10.1007/s00415-024-12291.
PubMed Abstract available

GUERRIERI S, Rubin M, Gattuso I, Zanetta C, et al
Can treatment adverse events be optimized by switching between different sphingosine 1-phosphate receptor modulators in multiple sclerosis? A case series.
J Neurol. 2024 Apr 2. doi: 10.1007/s00415-024-12342.
PubMed

TEDONE N, Vizzino C, Meani A, Gallo A, et al
The brief repeatable battery of neuropsychological tests (BRB-N) version a: update of Italian normative data from the Italian Neuroimaging Network Initiative (INNI).
J Neurol. 2024;271:1813-1823.
PubMed Abstract available

GLASER A, Butzkueven H, van der Walt A, Gray O, et al
Big Multiple Sclerosis Data network: an international registry research network.
J Neurol. 2024 Apr 1. doi: 10.1007/s00415-024-12303.
PubMed Abstract available

HUA T, Fan H, Duan Y, Tian D, et al
Spinal cord and brain atrophy patterns in neuromyelitis optica spectrum disorder and multiple sclerosis.
J Neurol. 2024 Apr 1. doi: 10.1007/s00415-024-12281.
PubMed Abstract available

March 2024

GUILLEMIN C, Vandeleene N, Charonitis M, Requier F, et al
Brain microstructure is linked to cognitive fatigue in early multiple sclerosis.
J Neurol. 2024 Mar 28. doi: 10.1007/s00415-024-12316.
PubMed Abstract available

SCHALLER-PAULE MA, Maiworm M, Schafer JH, Friedauer L, et al
Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.
J Neurol. 2024 Mar 27. doi: 10.1007/s00415-024-12299.
PubMed Abstract available

MALLUCCI G, Ferraro OE, Trojano M, Amato MP, et al
Early prediction of unfavorable evolution after a first clinical episode suggestive of multiple sclerosis: the EUMUS score.
J Neurol. 2024 Mar 26. doi: 10.1007/s00415-024-12304.
PubMed Abstract available

PILOTTO S, Floris M, Solla P, Pugliatti M, et al
Determinants of self-perceived quality of life in mildly disabled multiple sclerosis patients: a cross-sectional study.
J Neurol. 2024 Mar 25. doi: 10.1007/s00415-024-12244.
PubMed Abstract available

GOERECI Y, Ellenberger D, Rommer P, Dunkl V, et al
Persons with multiple sclerosis older than 55 years: an analysis from the German MS registry.
J Neurol. 2024 Mar 22. doi: 10.1007/s00415-024-12286.
PubMed Abstract available

ALBERGONI M, Pagani E, Preziosa P, Meani A, et al
Thalamic nuclei volume partially mediates the effects of aerobic capacity on fatigue in people with multiple sclerosis.
J Neurol. 2024 Mar 20. doi: 10.1007/s00415-024-12277.
PubMed Abstract available

ABDELGAIED MY, Rashad MH, El-Tayebi HM, Solayman MH, et al
Correction to: The impact of metformin use on the outcomes of relapse?remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open?label randomized controlled trial.
J Neurol. 2024 Mar 18. doi: 10.1007/s00415-024-12249.
PubMed

KRIJNEN EA, Broeders TAA, Noteboom S, van Dam M, et al
The cognitive relevance of non-lesional damage to cortical networks in people with multiple sclerosis.
J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12240.
PubMed Abstract available

HEGEN H, Berek K, Deisenhammer F, Berger T, et al
Sex impacts treatment decisions in multiple sclerosis.
J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12270.
PubMed Abstract available

HECHENBERGER S, Helmlinger B, Tinauer C, Jauk E, et al
Evaluation of a self-administered iPad((R))-based processing speed assessment for people with multiple sclerosis in a clinical routine setting.
J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12274.
PubMed Abstract available

ZID Y, Robertson NP
Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials.
J Neurol. 2024 Mar 4. doi: 10.1007/s00415-024-12273.
PubMed

GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
Early intensive versus escalation treatment in patients with relapsing-remitting multiple sclerosis in Austria.
J Neurol. 2024 Mar 2. doi: 10.1007/s00415-024-12256.
PubMed Abstract available

February 2024

SCHERER L, Soudant M, Pittion-Vouyovitch S, Debouverie M, et al
Risk of secondary progression in patients with highly active multiple sclerosis treated with natalizumab: a real-life study.
J Neurol. 2024 Feb 29. doi: 10.1007/s00415-024-12266.
PubMed Abstract available

TOLJAN K, Briggs FBS
Male sexual and reproductive health in multiple sclerosis: a scoping review.
J Neurol. 2024 Feb 28. doi: 10.1007/s00415-024-12250.
PubMed Abstract available

LEAVITT VM, Tozlu C, Nelson KE, Boehme AK, et al
A randomized controlled trial of oral antipyretic treatment to reduce overheating during exercise in adults with multiple sclerosis.
J Neurol. 2024 Feb 28. doi: 10.1007/s00415-023-12147.
PubMed Abstract available

VAN DAM M, Krijnen EA, Nauta IM, Fuchs TA, et al
Identifying and understanding cognitive profiles in multiple sclerosis: a role for visuospatial memory functioning.
J Neurol. 2024 Feb 26. doi: 10.1007/s00415-024-12227.
PubMed Abstract available

CUTILLO G, Rubin M, d'Amore G, Malcangi M, et al
Infratentorial posterior reversible encephalopathy syndrome in INFbeta1a-treated multiple sclerosis patient.
J Neurol. 2024 Feb 22. doi: 10.1007/s00415-024-12226.
PubMed

BIANCHI A, Matranga D, Patti F, Maniscalco L, et al
The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT).
J Neurol. 2024 Feb 16. doi: 10.1007/s00415-024-12214.
PubMed Abstract available

HARDING KE, Kreft KL, Ben-Shlomo Y, Robertson NP, et al
Prodromal multiple sclerosis: considerations and future utility.
J Neurol. 2024 Feb 11. doi: 10.1007/s00415-023-12173.
PubMed Abstract available

January 2024

BAJRAMI A, Tamanti A, Peloso A, Ziccardi S, et al
Ocrelizumab reduces cortical and deep grey matter loss compared to the S1P-receptor modulator in multiple sclerosis.
J Neurol. 2024 Jan 30. doi: 10.1007/s00415-023-12179.
PubMed Abstract available

BOUMAN PM, van Dam MA, Jonkman LE, Steenwijk MD, et al
Isolated cognitive impairment in people with multiple sclerosis: frequency, MRI patterns and its development over time.
J Neurol. 2024 Jan 30. doi: 10.1007/s00415-024-12185.
PubMed Abstract available

NAUTA IM, Kessels RPC, Bertens D, Stam CJ, et al
Neurophysiological brain function predicts response to cognitive rehabilitation and mindfulness in multiple sclerosis: a randomized trial.
J Neurol. 2024 Jan 26. doi: 10.1007/s00415-024-12183.
PubMed Abstract available

FENG G, Posa S, Sureshkumar A, Simpson S, et al
Experiences of people with multiple sclerosis and clinicians in using cognitive behavioural therapies for hidden symptoms: a systematic review and meta-aggregation.
J Neurol. 2024 Jan 14. doi: 10.1007/s00415-023-12116.
PubMed Abstract available

ZHENG P, Sandroff BM, Motl RW
Free-living ambulatory physical activity and cognitive function in multiple sclerosis: the significance of step rate vs. step volume.
J Neurol. 2024 Jan 12. doi: 10.1007/s00415-023-12169.
PubMed Abstract available

MAILLART E, Todesco E, Assoumou L, Beigneux Y, et al
Humoral response after accelerated schedule of HBV vaccination in MS patients before anti-CD20 therapy.
J Neurol. 2024 Jan 11. doi: 10.1007/s00415-023-12175.
PubMed

TRYFONOS C, Chrysafi M, Vadikolias K, Berberoglou L, et al
Nutritional interventional studies in patients with multiple sclerosis: a scoping review of the current clinical evidence.
J Neurol. 2024 Jan 4. doi: 10.1007/s00415-023-12140.
PubMed Abstract available

LOREFICE L, Ferraro OE, Fenu G, Amato MP, et al
Late-onset multiple sclerosis: disability trajectories in relapsing-remitting patients of the Italian MS Registry.
J Neurol. 2024 Jan 3. doi: 10.1007/s00415-023-12152.
PubMed Abstract available

MOSER T, Zimmermann G, Baumgartner A, Berger T, et al
Long-term outcome of natalizumab-associated progressive multifocal leukoencephalopathy in Austria: a nationwide retrospective study.
J Neurol. 2024;271:374-385.
PubMed Abstract available

December 2023

AZZIMONTI M, Margoni M, Zanetta C, Genovese F, et al
Tumefactive demyelinating lesions: a challenging first manifestation of multiple sclerosis.
J Neurol. 2023 Dec 28. doi: 10.1007/s00415-023-12164.
PubMed

IAFFALDANO P, Lucisano G, Guerra T, Patti F, et al
Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry.
J Neurol. 2023 Dec 22. doi: 10.1007/s00415-023-12137.
PubMed Abstract available

ANDORRA M, Freire A, Zubizarreta I, de Rosbo NK, et al
Predicting disease severity in multiple sclerosis using multimodal data and machine learning.
J Neurol. 2023 Dec 22. doi: 10.1007/s00415-023-12132.
PubMed Abstract available

MISTRI D, Valsasina P, Storelli L, Filippi M, et al
Monoaminergic network dysfunction and development of depression in multiple sclerosis: a longitudinal investigation.
J Neurol. 2023 Dec 19. doi: 10.1007/s00415-023-12138.
PubMed Abstract available

HABBESTAD A, Willumsen JS, Aarseth JH, Grytten N, et al
Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study.
J Neurol. 2023 Dec 14. doi: 10.1007/s00415-023-12047.
PubMed Abstract available

COVEY TJ, Golan D, Sergott R, Wilken J, et al
Peering further into the mind's eye: combining visual evoked potential and optical coherence tomography measures enhances insight into the variance in cognitive functioning in multiple sclerosis.
J Neurol. 2023 Dec 13. doi: 10.1007/s00415-023-12075.
PubMed Abstract available

ARROYO PEREIRO P, Munoz-Vendrell A, Leon Moreno I, Bau L, et al
Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.
J Neurol. 2023 Dec 12. doi: 10.1007/s00415-023-12135.
PubMed Abstract available

TSAI CC, Jette S, Tremlett H
Disease-modifying therapies used to treat multiple sclerosis and the gut microbiome: a systematic review.
J Neurol. 2023 Dec 11. doi: 10.1007/s00415-023-12107.
PubMed Abstract available

ABDELGAIED MY, Rashad MH, El-Tayebi HM, Solayman MH, et al
The impact of metformin use on the outcomes of relapse-remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open-label randomized controlled trial.
J Neurol. 2023 Dec 9. doi: 10.1007/s00415-023-12113.
PubMed Abstract available

November 2023

MEYER-ARNDT L, Brasanac J, Gamradt S, Bellmann-Strobl J, et al
Body mass, neuro-hormonal stress processing, and disease activity in lean to obese people with multiple sclerosis.
J Neurol. 2023 Nov 27. doi: 10.1007/s00415-023-12100.
PubMed Abstract available

MISTRI D, Tedone N, Biondi D, Vizzino C, et al
Cognitive phenotypes in multiple sclerosis: mapping the spectrum of impairment.
J Neurol. 2023 Nov 26. doi: 10.1007/s00415-023-12102.
PubMed Abstract available

JAKIMOVSKI D, Kavak KS, Coyle PK, Goodman AD, et al
Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.
J Neurol. 2023 Nov 23. doi: 10.1007/s00415-023-12099.
PubMed Abstract available

BISECCO A, Matrone F, Capobianco M, De Luca G, et al
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients.
J Neurol. 2023 Nov 20. doi: 10.1007/s00415-023-12084.
PubMed Abstract available

KENNEDY PGE, George W, Yu X
The elusive nature of the oligoclonal bands in multiple sclerosis.
J Neurol. 2023 Nov 9. doi: 10.1007/s00415-023-12081.
PubMed Abstract available

DI FILIPPO M, Ferraro D, Ragonese P, Prosperini L, et al
SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose.
J Neurol. 2023 Nov 3. doi: 10.1007/s00415-023-12034.
PubMed Abstract available

FROHLICH K, Mrochen A, Wang R, Haupenthal D, et al
Cerebral lesions sites in neurosarcoidosis: a lesion mapping study.
J Neurol. 2023;270:5392-5397.
PubMed Abstract available

JEANTIN L, Shor N, Pallix-Guyot M, Roos-Weil D, et al
Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod.
J Neurol. 2023 Nov 1. doi: 10.1007/s00415-023-12055.
PubMed

October 2023

MANTERO V, Cordano C, Balgera R, Basilico P, et al
Serum sickness in a multiple sclerosis patient treated with ocrelizumab.
J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-12082.
PubMed

KAPPOS L, Traboulsee A, Li DKB, Bar-Or A, et al
Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.
J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-11943.
PubMed Abstract available

DELGADO SR, Faissner S, Linker RA, Rammohan K, et al
Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment.
J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-12007.
PubMed Abstract available

RIVEL M, Achiron A, Stern Y, Zeilig G, et al
Emotional burden among MS patients: associations between specific chronic pain diagnoses and psychological features.
J Neurol. 2023 Oct 24. doi: 10.1007/s00415-023-12048.
PubMed Abstract available

ONTANEDA D, Chitnis T, Rammohan K, Obeidat AZ, et al
Identification and management of subclinical disease activity in early multiple sclerosis: a review.
J Neurol. 2023 Oct 21. doi: 10.1007/s00415-023-12021.
PubMed Abstract available

ZINGANELL A, Gobel G, Berek K, Hofer B, et al
Multiple sclerosis in the elderly: a retrospective cohort study.
J Neurol. 2023 Oct 19. doi: 10.1007/s00415-023-12041.
PubMed Abstract available

SELMAJ K, Cree BAC, Barnett M, Thompson A, et al
Multiple sclerosis: time for early treatment with high-efficacy drugs.
J Neurol. 2023 Oct 18. doi: 10.1007/s00415-023-11969.
PubMed Abstract available

RAVANO V, Piredda GF, Krasensky J, Andelova M, et al
Tract-wise microstructural analysis informs on current and future disability in early multiple sclerosis.
J Neurol. 2023 Oct 11. doi: 10.1007/s00415-023-12023.
PubMed Abstract available

September 2023

RODRIGUEZ DE VERA GOMEZ P, Mendez Muros M, Torres Cuadro A, Toyos Saenz de Miera FJ, et al
Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis.
J Neurol. 2023 Sep 29. doi: 10.1007/s00415-023-11995.
PubMed Abstract available

LI Y, Saul A, Taylor B, Ponsonby AL, et al
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.
J Neurol. 2023 Sep 28. doi: 10.1007/s00415-023-11980.
PubMed Abstract available

WEEDA MM, van Nederpelt DR, Twisk JWR, Brouwer I, et al
Multimodal MRI study on the relation between WM integrity and connected GM atrophy and its effect on disability in early multiple sclerosis.
J Neurol. 2023 Sep 17. doi: 10.1007/s00415-023-11937.
PubMed Abstract available

FILIPPI M, Grimaldi L, Conte A, Totaro R, et al
Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study.
J Neurol. 2023 Sep 16. doi: 10.1007/s00415-023-11955.
PubMed Abstract available

MCARTHUR C, Daruwalla C, Jayeskara M, Brown JWL, et al
Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis.
J Neurol. 2023 Sep 12. doi: 10.1007/s00415-023-11984.
PubMed

JACOBS BM, Tank P, Bestwick JP, Noyce AJ, et al
Modifiable risk factors for multiple sclerosis have consistent directions of effect across diverse ethnic backgrounds: a nested case-control study in an English population-based cohort.
J Neurol. 2023 Sep 7. doi: 10.1007/s00415-023-11971.
PubMed Abstract available

August 2023

FERRAND M, Epstein J, Soudant M, Guillemin F, et al
Real-life evaluation of the 2017 McDonald criteria for relapsing-remitting multiple sclerosis after a clinically isolated syndrome confirms a gain in time-to-diagnosis.
J Neurol. 2023 Aug 31. doi: 10.1007/s00415-023-11905.
PubMed Abstract available

BONACCHI R, Valsasina P, Pagani E, Meani A, et al
Sex-related differences in upper limb motor function in healthy subjects and multiple sclerosis patients: a multiparametric MRI study.
J Neurol. 2023 Aug 28. doi: 10.1007/s00415-023-11948.
PubMed Abstract available

TOSCANO S, Chisari CG, Lo Fermo S, Gulino G, et al
A dynamic interpretation of kappaFLC index for the diagnosis of multiple sclerosis: a change of perspective.
J Neurol. 2023 Aug 28. doi: 10.1007/s00415-023-11952.
PubMed Abstract available

JAKIMOVSKI D, Zivadinov R, Weinstock Z, Fuchs TA, et al
Cortical thickness and cognition in older people with multiple sclerosis.
J Neurol. 2023 Aug 27. doi: 10.1007/s00415-023-11945.
PubMed Abstract available

SPIERER R, Lavi I, Bloch S, Mazar M, et al
Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies.
J Neurol. 2023 Aug 17. doi: 10.1007/s00415-023-11935.
PubMed Abstract available

KLETENIK I, Cohen AL, Glanz BI, Ferguson MA, et al
Multiple sclerosis lesions that impair memory map to a connected memory circuit.
J Neurol. 2023 Aug 2. doi: 10.1007/s00415-023-11907.
PubMed Abstract available

July 2023

TILSLEY P, Strohmeyer IA, Heinrich I, Rosenthal F, et al
Correction to: Physical fitness moderates the association between brain network impairment and both motor function and cognition in progressive multiple sclerosis.
J Neurol. 2023 Jul 26. doi: 10.1007/s00415-023-11874.
PubMed

NOTEBOOM S, van Nederpelt DR, Bajrami A, Moraal B, et al
Feasibility of detecting atrophy relevant for disability and cognition in multiple sclerosis using 3D-FLAIR.
J Neurol. 2023 Jul 19. doi: 10.1007/s00415-023-11870.
PubMed Abstract available

ROCCA MA, Valsasina P, Lamanna MT, Colombo B, et al
Functional connectivity modifications in monoaminergic circuits occur in fatigued MS patients treated with fampridine and amantadine.
J Neurol. 2023 Jul 18. doi: 10.1007/s00415-023-11858.
PubMed Abstract available

LOMBARDO-DEL TORO P, Bragado-Trigo I, Arroyo P, Tena-Cucala R, et al
Fingolimod-associated progressive multifocal leukoencephalopathy in a multiple sclerosis patient with a good response to filgrastim.
J Neurol. 2023 Jul 17. doi: 10.1007/s00415-023-11865.
PubMed

PETROU P, Achiron A, Cohen EG, Garty M, et al
Practical recommendations on treatment of multiple sclerosis with Cladribine: an Israeli Experts Groupâ€ Viewpoint.
J Neurol. 2023 Jul 12. doi: 10.1007/s00415-023-11846.
PubMed Abstract available

AMATO MP, Bergamaschi R, Centonze D, Mirabella M, et al
Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study.
J Neurol. 2023 Jul 5. doi: 10.1007/s00415-023-11820.
PubMed Abstract available

NICULAE AS, Niculae LE, Vacaras C, Vacaras V, et al
Serum levels of neurofilament light chains in pediatric multiple sclerosis: a systematic review and meta-analysis.
J Neurol. 2023 Jul 2. doi: 10.1007/s00415-023-11841.
PubMed Abstract available

JARIUS S, Aktas O, Ayzenberg I, Bellmann-Strobl J, et al
Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.
J Neurol. 2023;270:3341-3368.
PubMed Abstract available

June 2023

RUGGIERI S, Prosperini L, Petracca M, Logoteta A, et al
The added value of spinal cord lesions to disability accrual in multiple sclerosis.
J Neurol. 2023 Jun 29. doi: 10.1007/s00415-023-11829.
PubMed Abstract available

TILSLEY P, Strohmeyer IA, Heinrich I, Rosenthal F, et al
Physical fitness moderates the association between brain network impairment and both motor function and cognition in progressive multiple sclerosis.
J Neurol. 2023 Jun 21. doi: 10.1007/s00415-023-11806.
PubMed Abstract available

ROSENSTEIN I, Axelsson M, Novakova L, Malmestrom C, et al
Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing-remitting multiple sclerosis.
J Neurol. 2023 Jun 14. doi: 10.1007/s00415-023-11817.
PubMed Abstract available

GRANGE E, Solaro C, Di Giovanni R, Marengo D, et al
The correlation between 9-HPT and patient-reported measures of upper limb function in multiple sclerosis: a systematic review and meta-analysis.
J Neurol. 2023 Jun 9. doi: 10.1007/s00415-023-11801.
PubMed Abstract available

MONSCHEIN T, Dekany S, Zrzavy T, Ponleitner M, et al
Correction: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).
J Neurol. 2023 Jun 5. doi: 10.1007/s00415-023-11784.
PubMed

HOLTZER R, Choi J, Motl RW, Foley FW, et al
Individual reserve in aging and neurological disease.
J Neurol. 2023;270:3179-3191.
PubMed Abstract available

May 2023

LOUAPRE C, Rosenzwajg M, Golse M, Roux A, et al
A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing-remitting multiple sclerosis.
J Neurol. 2023 May 28. doi: 10.1007/s00415-023-11690.
PubMed Abstract available

AZZIMONTI M, Preziosa P, Pagani E, Valsasina P, et al
Functional and structural brain MRI changes associated with cognitive worsening in multiple sclerosis: a 3-year longitudinal study.
J Neurol. 2023 May 18. doi: 10.1007/s00415-023-11778.
PubMed Abstract available

ZANETTA C, Rocca MA, Meani A, Martinelli V, et al
Correction to: Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
J Neurol. 2023 May 17. doi: 10.1007/s00415-023-11772.
PubMed

MUNOZ-VENDRELL A, Arroyo-Pereiro P, Leon I, Bau L, et al
Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment.
J Neurol. 2023;270:2559-2566.
PubMed Abstract available

April 2023

KREMMYDA O, Feil K, Bardins S, Strupp M, et al
Acetyl-DL-leucine in combination with memantine improves acquired pendular nystagmus caused by multiple sclerosis: a case report.
J Neurol. 2023 Apr 27. doi: 10.1007/s00415-023-11730.
PubMed

VAN DAM M, de Jong BA, Willemse EAJ, Nauta IM, et al
A multimodal marker for cognitive functioning in multiple sclerosis: the role of NfL, GFAP and conventional MRI in predicting cognitive functioning in a prospective clinical cohort.
J Neurol. 2023 Apr 27. doi: 10.1007/s00415-023-11676.
PubMed Abstract available

MARGONI M, Pagani E, Preziosa P, Gueye M, et al
Unraveling the heterogeneous pathological substrates of relapse-onset multiple sclerosis: a multiparametric voxel-wise 3 T MRI study.
J Neurol. 2023 Apr 24. doi: 10.1007/s00415-023-11736.
PubMed Abstract available

KOUTSOURAKI E, Theodoros K, Eleni G, Marianna K, et al
Autonomic nervous system disorders in multiple sclerosis.
J Neurol. 2023 Apr 21. doi: 10.1007/s00415-023-11725.
PubMed Abstract available

MONSCHEIN T, Dekany S, Zrzavy T, Ponleitner M, et al
Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).
J Neurol. 2023 Apr 19. doi: 10.1007/s00415-023-11686.
PubMed Abstract available

GANAPATHY SUBRAMANIAN R, Zivadinov R, Bergsland N, Dwyer MG, et al
Multiple sclerosis optic neuritis and trans-synaptic pathology on cortical thinning in people with multiple sclerosis.
J Neurol. 2023 Apr 17. doi: 10.1007/s00415-023-11709.
PubMed Abstract available

YEO T, Siew RWE, Gulam MY, Tye JSN, et al
COVID-19 infection after SARS-CoV-2 mRNA vaccination in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD patients during the Omicron subvariant BA.1/2 wave in Singapore.
J Neurol. 2023 Apr 7:1-9. doi: 10.1007/s00415-023-11692.
PubMed Abstract available

ZANETTA C, Rocca MA, Meani A, Martinelli V, et al
Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
J Neurol. 2023 Apr 7:1-12. doi: 10.1007/s00415-023-11700.
PubMed Abstract available

VRENKEN H, Battaglini M, de Vos ML, Nagtegaal GJ, et al
Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon beta-1a.
J Neurol. 2023;270:2271-2282.
PubMed Abstract available

LEHTO J, Sucksdorff M, Nylund M, Raitanen R, et al
PET-measurable innate immune cell activation reduction in chronic active lesions in PPMS brain after rituximab treatment: a case report.
J Neurol. 2023;270:2329-2332.
PubMed Abstract available

ASTBURY L, Kalra S, Tanasescu R, Constantinescu CS, et al
CSF lymphocytic pleocytosis does not predict a less favourable long-term prognosis in MS.
J Neurol. 2023;270:2042-2047.
PubMed Abstract available

March 2023

PLESS S, Woelfle T, Naegelin Y, Lorscheider J, et al
Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study.
J Neurol. 2023 Mar 23. doi: 10.1007/s00415-023-11671.
PubMed Abstract available

TORRES P, Sancho-Saldana A, Gil Sanchez A, Peralta S, et al
A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.
J Neurol. 2023 Mar 18:1-12. doi: 10.1007/s00415-023-11575.
PubMed Abstract available

ROMANO F, Motl RW, Valsasina P, Amato MP, et al
Abnormal thalamic functional connectivity correlates with cardiorespiratory fitness and physical activity in progressive multiple sclerosis.
J Neurol. 2023 Mar 18. doi: 10.1007/s00415-023-11664.
PubMed Abstract available

DE ROSA AP, Esposito F, Valsasina P, d'Ambrosio A, et al
Correction to: Resting-state functional MRI in multicenter studies on multiple sclerosis: a report on raw data quality and functional connectivity features from the Italian Neuroimaging Network Initiative.
J Neurol. 2023 Mar 13. doi: 10.1007/s00415-023-11646.
PubMed

MOGAVERO MP, Lanza G, Bruni O, DelRosso LM, et al
Sleep counts! Role and impact of sleep in the multimodal management of multiple sclerosis.
J Neurol. 2023 Mar 11. doi: 10.1007/s00415-023-11655.
PubMed Abstract available

VELDKAMP R, D'hooge M, Sandroff BM, DeLuca J, et al
Profiling cognitive-motor interference in a large sample of persons with progressive multiple sclerosis and impaired processing speed: results from the CogEx study.
J Neurol. 2023 Mar 7. doi: 10.1007/s00415-023-11636.
PubMed Abstract available

LI G, You Q, Hou X, Zhang S, et al
The effect of exercise on cognitive function in people with multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials.
J Neurol. 2023 Mar 2. doi: 10.1007/s00415-023-11649.
PubMed Abstract available

GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing-remitting multiple sclerosis in Austria.
J Neurol. 2023 Mar 2. doi: 10.1007/s00415-023-11644.
PubMed Abstract available

BARLETTA VT, Herranz E, Treaba CA, Mehndiratta A, et al
In vivo characterization of microglia and myelin relation in multiple sclerosis by combined (11)C-PBR28 PET and synthetic MRI.
J Neurol. 2023 Mar 2. doi: 10.1007/s00415-023-11621.
PubMed Abstract available

DIETMANN AS, Kruse N, Stork L, Gloth M, et al
Neurofilament light chains in serum as biomarkers of axonal damage in early MS lesions: a histological-serological correlative study.
J Neurol. 2023;270:1416-1429.
PubMed Abstract available

February 2023

BAETGE SJ, Filser M, Renner A, Raithel LM, et al
Supporting brain health in multiple sclerosis: exploring the potential of neuroeducation combined with practical mindfulness exercises in the management of neuropsychological symptoms.
J Neurol. 2023 Feb 25:1-14. doi: 10.1007/s00415-023-11616.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum